All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 > 1% PD-L1 > 10% smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced UC (mUC) - 2nd Line (L2), anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-211 (all population), 2018 0.85 [0.73; 0.99]
IMvigor-211 (PDL1>1%), 2018 0.87 [0.72; 1.06]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.63; 1.21]
KEYNOTE-045 (all population), 2017 0.73 [0.59; 0.91]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.57 [0.37; 0.88]
0.81 [0.73 ; 0.90 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017 5 11% 2,496 moderate not evaluable deaths (OS) (extension)detailed results IMvigor-211 (all population), 2018 0.82 [0.71; 0.94]
IMvigor-211 (PDL1>5%), 2018 0.87 [0.64; 1.18]
KEYNOTE-045 (all population), 2017 0.70 [0.57; 0.85]
0.79 [0.71 ; 0.88 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 3% 1,707 moderate not evaluable PFS (extension)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.79; 1.16]
0.96 [0.79 ; 1.16 ] KEYNOTE-045 (all population), 2017 1 0% 542 NA not evaluable progression or deaths (PFS)detailed results IMvigor-211 (all population), 2018 0.89 [0.60; 1.32]
IMvigor-211 (PDL1>1%), 2018 0.86 [0.53; 1.39]
IMvigor-211 (PDL1>5%), 2018 1.01 [0.76; 1.35]
KEYNOTE-045 (all population), 2017 0.98 [0.81; 1.19]
KEYNOTE-045 (PDL1 CPS >10%), 2017 0.89 [0.61; 1.29]
0.95 [0.84 ; 1.09 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017 5 0% 2,496 moderate serious DORdetailed results IMvigor-211 (all population), 2018 0.16 [0.07; 0.35]
IMvigor-211 (PDL1>1%), 2018 0.20 [0.08; 0.50]
IMvigor-211 (PDL1>5%), 2018 0.16 [0.04; 0.55]
KEYNOTE-045 (all population), 2017 4.66 [1.83; 11.87]
0.39 [0.07 ; 2.06 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 4 92% 352 moderate not evaluable objective responses (ORR)detailed results IMvigor-211 (all population), 2018 0.99 [0.68; 1.45]
IMvigor-211 (PDL1>1%), 2018 0.95 [0.61; 1.49]
IMvigor-211 (PDL1>5%), 2018 1.07 [0.58; 2.00]
KEYNOTE-045 (all population), 2017 2.08 [1.29; 3.34]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.86 [1.43; 10.46]
1.37 [0.90 ; 2.09 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>1%), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017 5 68% 2,496 moderate not evaluable objective responses (ORR) (extension)detailed results KEYNOTE-045 (all population), 2017 2.16 [1.34; 3.48]
KEYNOTE-045 (PDL1 CPS >10%), 2017 3.56 [1.30; 9.71]
2.37 [1.54 ; 3.65 ] KEYNOTE-045 (all population), 2017, KEYNOTE-045 (PDL1 CPS >10%), 2017 2 0% 706 moderate not evaluable AE (any grade)detailed results IMvigor-211 (all population), 2018 0.38 [0.17; 0.88]
IMvigor-211 (PDL1>5%), 2018 0.67 [0.11; 4.10]
KEYNOTE-045 (all population), 2017 0.28 [0.10; 0.75]
0.36 [0.20 ; 0.66 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable AE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.80 [0.62; 1.04]
IMvigor-211 (PDL1>5%), 2018 1.38 [0.81; 2.33]
KEYNOTE-045 (all population), 2017 0.61 [0.43; 0.86]
0.84 [0.57 ; 1.22 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 69% 1,649 moderate not evaluable AE leading to death (grade 5)detailed results IMvigor-211 (all population), 2018 0.91 [0.46; 1.79]
IMvigor-211 (PDL1>5%), 2018 0.73 [0.16; 3.34]
KEYNOTE-045 (all population), 2017 1.59 [0.65; 3.89]
1.06 [0.64 ; 1.76 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.37 [0.24; 0.57]
IMvigor-211 (PDL1>5%), 2018 0.44 [0.20; 0.99]
KEYNOTE-045 (all population), 2017 0.63 [0.35; 1.11]
0.45 [0.33 ; 0.62 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 1% 1,649 moderate not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.85 [0.44; 1.65]
0.85 [0.44 ; 1.65 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable SAE (any grade)detailed results IMvigor-211 (all population), 2018 0.92 [0.70; 1.19]
IMvigor-211 (PDL1>5%), 2018 1.79 [1.05; 3.05]
1.23 [0.64 ; 2.37 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 80% 1,128 moderate not evaluable STRAE (any grade)detailed results IMvigor-211 (all population), 2018 0.56 [0.40; 0.78]
IMvigor-211 (PDL1>5%), 2018 0.92 [0.48; 1.80]
0.66 [0.42 ; 1.04 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 41% 1,128 moderate not evaluable TRAE (any grade)detailed results IMvigor-211 (all population), 2018 0.28 [0.19; 0.40]
IMvigor-211 (PDL1>5%), 2018 0.38 [0.19; 0.79]
KEYNOTE-045 (all population), 2017 0.17 [0.10; 0.28]
0.25 [0.17 ; 0.38 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 52% 1,649 moderate not evaluable TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.33 [0.25; 0.45]
IMvigor-211 (PDL1>5%), 2018 0.55 [0.31; 0.99]
KEYNOTE-045 (all population), 2017 0.19 [0.12; 0.28]
0.32 [0.19 ; 0.54 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 79% 1,649 moderate not evaluable TRAE leading to death (grade 5)detailed results IMvigor-211 (all population), 2018 0.42 [0.13; 1.39]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.14; 7.10]
KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
0.65 [0.29 ; 1.48 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results IMvigor-211 (all population), 2018 0.22 [0.12; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.37 [0.15; 0.92]
KEYNOTE-045 (all population), 2017 0.48 [0.25; 0.93]
0.33 [0.19 ; 0.55 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 41% 1,649 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.40 [0.18; 0.89]
IMvigor-211 (PDL1>5%), 2018 0.98 [0.19; 4.97]
KEYNOTE-045 (all population), 2017 0.07 [0.02; 0.31]
0.31 [0.09 ; 1.10 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 67% 1,649 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.42 [0.18; 0.97]
IMvigor-211 (PDL1>5%), 2018 0.49 [0.04; 5.45]
KEYNOTE-045 (all population), 2017 0.13 [0.02; 1.09]
0.37 [0.17 ; 0.78 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
5.81 [0.29 ; 116.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Constipation TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.02 [0.00; 0.38]
IMvigor-211 (PDL1>5%), 2018 0.12 [0.01; 2.28]
KEYNOTE-045 (all population), 2017 0.06 [0.00; 1.02]
0.05 [0.01 ; 0.28 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.44 [0.24; 8.71]
1.44 [0.24 ; 8.71 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.37 [0.15; 0.88]
IMvigor-211 (PDL1>5%), 2018 2.00 [0.36; 11.15]
KEYNOTE-045 (all population), 2017 0.25 [0.07; 0.92]
0.48 [0.18 ; 1.31 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 48% 1,649 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.00; 0.27]
IMvigor-211 (PDL1>5%), 2018 0.09 [0.01; 1.75]
0.05 [0.01 ; 0.26 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018 2 0% 1,128 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.03; 2.13]
0.24 [0.03 ; 2.13 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
3.86 [0.17 ; 85.92 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.04 [0.01; 0.15]
IMvigor-211 (PDL1>5%), 2018 0.20 [0.04; 0.97]
KEYNOTE-045 (all population), 2017 0.01 [0.00; 0.19]
0.06 [0.01 ; 0.25 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 53% 1,649 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMvigor-211 (all population), 2018 0.12 [0.01; 0.95]
IMvigor-211 (PDL1>5%), 2018 0.32 [0.03; 3.14]
KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.20 [0.05 ; 0.78 ] IMvigor-211 (all population), 2018, IMvigor-211 (PDL1>5%), 2018, KEYNOTE-045 (all population), 2017 3 0% 1,649 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 9.75 [0.53; 179.40]
9.75 [0.53 ; 179.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.32 [0.03; 3.07]
0.32 [0.03 ; 3.07 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.40 [0.10; 1.58]
0.40 [0.10 ; 1.58 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.27 [0.58; 8.88]
2.27 [0.58 ; 8.88 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Alopecia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.65 [0.37; 1.16]
0.65 [0.37 ; 1.16 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.01; 3.17]
0.16 [0.01 ; 3.17 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.14 [0.03; 0.63]
0.14 [0.03 ; 0.63 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.15; 0.40]
0.24 [0.15 ; 0.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.17; 21.35]
1.92 [0.17 ; 21.35 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Cardiac disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.72 [0.16; 3.23]
0.72 [0.16 ; 3.23 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.35 [0.09; 1.34]
0.35 [0.09 ; 1.34 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.28 [0.89; 12.06]
3.28 [0.89 ; 12.06 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.24; 3.87]
0.96 [0.24 ; 3.87 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dry skin AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dysgeusia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.61 [0.38; 6.80]
1.61 [0.38 ; 6.80 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Endocrine disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
5.81 [0.29 ; 116.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Eye disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
3.86 [0.17 ; 85.92 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.63 [0.28; 1.42]
0.63 [0.28 ; 1.42 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.02 [0.00; 0.39]
0.02 [0.00 ; 0.39 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.42 [0.24; 0.75]
0.42 [0.24 ; 0.75 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.49 [0.28; 0.86]
0.49 [0.28 ; 0.86 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Headache AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.02; 48.49]
0.96 [0.02 ; 48.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 11.75 [0.65; 211.40]
11.75 [0.65 ; 211.40 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 5.81 [0.29; 116.49]
5.81 [0.29 ; 116.49 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Infections and infestations AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.22 [0.72; 2.06]
1.22 [0.72 ; 2.06 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Injury, poisoning and procedure AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.45 [0.40; 5.19]
1.45 [0.40 ; 5.19 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Investigations AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.46 [0.26; 0.79]
0.46 [0.26 ; 0.79 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.07 [0.62; 1.84]
1.07 [0.62 ; 1.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.03; 2.13]
0.24 [0.03 ; 2.13 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Musculoskeletal and connective tissue disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.36 [0.59; 3.12]
1.36 [0.59 ; 3.12 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Myalgia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.72 [0.16; 3.23]
0.72 [0.16 ; 3.23 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Nervous system disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.27 [0.10; 0.74]
0.27 [0.10 ; 0.74 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.01 [0.00; 0.18]
0.01 [0.00 ; 0.18 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.24 [0.01; 5.31]
0.24 [0.01 ; 5.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.48 [0.02; 14.32]
0.48 [0.02 ; 14.32 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.64 [0.11; 3.84]
0.64 [0.11 ; 3.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.92 [0.06; 57.51]
1.92 [0.06 ; 57.51 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Renal and urinary disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.77 [1.31; 5.84]
2.77 [1.31 ; 5.84 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 1.63 [0.70; 3.80]
1.63 [0.70 ; 3.80 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.16 [0.02; 1.31]
0.16 [0.02 ; 1.31 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.06; 15.41]
0.96 [0.06 ; 15.41 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Vascular disorders AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 2.71 [0.85; 8.61]
2.71 [0.85 ; 8.61 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 0.96 [0.06; 15.41]
0.96 [0.06 ; 15.41 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable Weight decreased AE (grade 3-4)detailed results KEYNOTE-045 (all population), 2017 3.86 [0.17; 85.92]
3.86 [0.17 ; 85.92 ] KEYNOTE-045 (all population), 2017 1 0% 521 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 05:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 290,155,154
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563